Xencor (NASDAQ:XNCR) Issues Quarterly Earnings Results, Beats Estimates By $0.27 EPS

Xencor (NASDAQ:XNCR) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.98) by $0.27, Briefing.com reports. Xencor had a negative net margin of 132.74% and a negative return on equity of 28.23%. The firm had revenue of $10.70 million during the quarter, compared to the consensus estimate of $14.59 million. During the same period last year, the firm posted ($0.40) EPS. The firm’s quarterly revenue was down 81.9% on a year-over-year basis.

Xencor Stock Performance

Shares of XNCR stock traded up $0.54 on Thursday, hitting $23.22. The company’s stock had a trading volume of 370,486 shares, compared to its average volume of 596,248. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.92 and a current ratio of 6.92. The stock’s 50 day moving average is $20.21 and its 200-day moving average is $20.21. Xencor has a fifty-two week low of $15.31 and a fifty-two week high of $26.84. The company has a market capitalization of $1.62 billion, a PE ratio of -7.88 and a beta of 0.66.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Royal Bank of Canada lifted their price target on shares of Xencor from $31.00 to $34.00 and gave the company an “outperform” rating in a report on Thursday, September 26th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $32.00 target price on shares of Xencor in a research note on Tuesday, August 6th. JPMorgan Chase & Co. boosted their target price on shares of Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a research note on Thursday. Finally, Wedbush reaffirmed an “outperform” rating and issued a $38.00 target price on shares of Xencor in a research note on Thursday. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Xencor has an average rating of “Moderate Buy” and a consensus price target of $35.33.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.